Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH EBITDA Margin

EBITDA as a percentage of revenue.

Nyxoah S.A.NASDAQ: NYXH

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -198.7%

EBITDA Margin was -198.7% in Q1 FY2026, up 1794.0 pp from a year earlier. On a trailing-twelve-month basis it was -472.8%, up 983.8 pp year over year. Over 3 fiscal years it widened by 76.9 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -88.9% for the fiscal year ending Dec 2026, up from -827.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-198.7%+182.3 pp QoQ
Last fiscal yearDec 2025
-827.4%+361.9 pp YoY
LTMMar 2026
-472.8%+983.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1794.0 pp+1096.4 pp-697.5 pp
1 year+361.9 pp+738.4 pp+376.6 pp
3 years+76.9 pp+845.3 pp+768.4 pp
5 years+861.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-827.4%
Year-over-year change
+361.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NYXH compares with its peers on the latest reported figures

  • NYXH's LTM Mar 2026 EBITDA Margin of -472.8% is the 8th highest of the 9 companies compared; the peer median is -50.9%.
  • Its year-over-year change of +983.8 pp is the highest of 9, against a peer median of +18.1 pp.
  • Over three fiscal years its change of +76.9 pp compares with a peer median of -8.8 pp.
NYXH Competitors Peer median
EBITDA Margin for NYXH and competitors
Company Period LTM level YoY 3-year change
UTMDUtah Medical Products, Inc.LTM Mar 202643.6% -2.2 pp-8.8 pp
KRMDKORU Medical Systems, Inc.LTM Mar 2026-3.4% +9.6 pp+31.8 pp
STIMNeuronetics, Inc.LTM Mar 2026-17.0% +26.6 pp+30.8 pp
PREPrenetics Global LimitedLTM Mar 2026-45.4% +91.4 pp+1621.5 pp
OSUROraSure Technologies, Inc.LTM Mar 2026-56.4% -42.7 pp-49.1 pp
OABIOmniAb, Inc.LTM Mar 2026-117.0% +50.4 pp-225.4 pp
IVVDInvivyd, Inc.LTM Mar 2026-135.5% +244.4 pp—
NYXHNyxoah S.A.LTM Mar 2026-472.8% +983.8 pp+76.9 pp
CATXPerspective Therapeutics, Inc.LTM Mar 2026-17902.8% -12192.4 pp-11194.0 pp
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding NYXH) -50.9%+18.1 pp-8.8 pp

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.